| 251 |
20222756 | Dasatinib: is it all in the dose? | 2010 Jun |
2 |
| 252 |
20225261 | The tyrosine kinase inhibitor dasatinib dysregulates bone remodeling through inhibition of osteoclasts in vivo. | 2010 Aug |
1 |
| 253 |
20305692 | Bortezomib decreases Rb phosphorylation and induces caspase-dependent apoptosis in Imatinib-sensitive and -resistant Bcr-Abl1-expressing cells. | 2010 Jun 3 |
1 |
| 254 |
20375898 | Pleural effusions due to dasatinib. | 2010 Jul |
1 |
| 255 |
20406945 | Dasatinib is preclinically active against Src-overexpressing human transitional cell carcinoma of the urothelium with activated Src signaling. | 2010 May |
1 |
| 256 |
20447687 | A T315I mutation in e19a2 BCR/ABL1 chronic myeloid leukemia responding to dasatinib. | 2010 Sep |
1 |
| 257 |
20460883 | Pre-emptive treatment with nilotinib after second allogeneic transplantation in a Philadelphia chromosome-positive acute lymphoblastic leukemia patient with high risk of relapse. | 2010 |
1 |
| 258 |
20529808 | Clinical algorithms for the treatment of patients with chronic myeloid leukemia: the 2010 perspective. | 2010 Jun |
1 |
| 259 |
20537386 | BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: a review. | 2010 Oct |
2 |
| 260 |
20557276 | Novel dual Src/Abl inhibitors for hematologic and solid malignancies. | 2010 Aug |
1 |
| 261 |
20585556 | Role of Abl kinase and the Wave2 signaling complex in HIV-1 entry at a post-hemifusion step. | 2010 Jun 17 |
1 |
| 262 |
20597967 | Standard treatment of Ph+ CML in 2010: how, when and where not to use what BCR/ABL1 kinase inhibitor? | 2010 Oct |
1 |
| 263 |
20615173 | Cost-effectiveness of dasatinib versus high-dose imatinib in patients with Chronic Myeloid Leukemia (CML), resistant to standard dose imatinib--a Swedish model application. | 2010 Aug |
1 |
| 264 |
20629079 | Dasatinib induces autophagic cell death in human ovarian cancer. | 2010 Nov 1 |
1 |
| 265 |
20860375 | Photocleavable peptide-conjugated magnetic beads for protein kinase assays by MALDI-TOF MS. | 2010 Oct 20 |
1 |
| 266 |
20875551 | Chronic myeloid leukemia and second-generation tyrosine kinase inhibitors: when, how, and which one? | 2010 Oct |
1 |
| 267 |
20922699 | [Cancer treatment-induced nephrotoxicity: BCR-Abl and VEGF inhibitors]. | 2010 Sep-Oct |
1 |
| 268 |
21108851 | First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib. | 2010 Nov 26 |
2 |
| 269 |
18978822 | Dasatinib-induced restoration of donor chimerism in BCR-ABL1-positive ALL after failure of imatinib therapy and allo-SCT. | 2009 Apr |
1 |
| 270 |
18984583 | Crystal structures of the Lyn protein tyrosine kinase domain in its Apo- and inhibitor-bound state. | 2009 Jan 2 |
1 |
| 271 |
19013641 | Preclinical and clinical experience with dasatinib in Philadelphia chromosome-negative leukemias and myeloid disorders. | 2009 May |
1 |
| 272 |
19100678 | Combined BCR-ABL inhibition with lentiviral-delivered shRNA and dasatinib augments induction of apoptosis in Philadelphia-positive cells. | 2009 Feb |
4 |
| 273 |
19190119 | Dasatinib-induced autophagy is enhanced in combination with temozolomide in glioma. | 2009 Feb |
1 |
| 274 |
19195046 | Dasatinib treatment for Philadelphia chromosome-positive leukemias: practical considerations. | 2009 Apr 1 |
1 |
| 275 |
19236716 | New dosing schedules of dasatinib for CML and adverse event management. | 2009 Feb 23 |
1 |
| 276 |
19236722 | The structure of the leukemia drug imatinib bound to human quinone reductase 2 (NQO2). | 2009 Feb 24 |
1 |
| 277 |
19275507 | New approved dasatinib regimen available for clinical use. | 2009 Mar |
1 |
| 278 |
19282395 | Characterization of dasatinib and its structural analogs as CYP3A4 mechanism-based inactivators and the proposed bioactivation pathways. | 2009 Jun |
1 |
| 279 |
19295545 | Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy. | 2009 Aug |
1 |
| 280 |
19296866 | Protein kinase inhibitors: contributions from structure to clinical compounds. | 2009 Feb |
1 |
| 281 |
19363859 | Hair depigmentation during chemotherapy with dasatinib, a dual Bcr-Abl/Src family tyrosine kinase inhibitor. | 2009 Apr |
2 |
| 282 |
19369231 | Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up. | 2009 Jun 18 |
2 |
| 283 |
19395585 | Phase I study of the effect of gastric acid pH modulators on the bioavailability of oral dasatinib in healthy subjects. | 2009 Jun |
1 |
| 284 |
19402171 | Dasatinib early intervention after cytogenetic or hematologic resistance to imatinib in patients with chronic myeloid leukemia. | 2009 Jul 1 |
1 |
| 285 |
19455391 | Clinical profile of dasatinib in Asian and non-Asian patients with chronic myeloid leukemia. | 2009 Jun |
1 |
| 286 |
19487385 | Dasatinib in the treatment of chronic myeloid leukemia in accelerated phase after imatinib failure: the START a trial. | 2009 Jul 20 |
1 |
| 287 |
19494352 | The new tyrosine-kinase inhibitor and anticancer drug dasatinib reversibly affects platelet activation in vitro and in vivo. | 2009 Aug 27 |
1 |
| 288 |
19502190 | A once-daily dasatinib dosing strategy for chronic myeloid leukemia. | 2009 Jun |
1 |
| 289 |
19502192 | Practical management of dasatinib for maximum patient benefit. | 2009 Jun |
1 |
| 290 |
19536317 | Dasatinib in chronic myeloid leukemia: a review. | 2009 Apr |
1 |
| 291 |
19608684 | A co-operative evaluation of different methods of detecting BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia on second-line dasatinib or nilotinib therapy after failure of imatinib. | 2009 Sep |
1 |
| 292 |
19641527 | Dasatinib-associated major molecular responses in patients with chronic myeloid leukemia in chronic phase following imatinib failure: response dynamics and predictive value. | 2009 Sep |
1 |
| 293 |
19651622 | Global effects of kinase inhibitors on signaling networks revealed by quantitative phosphoproteomics. | 2009 Dec |
1 |
| 294 |
19672773 | Activation of the p38 Map kinase pathway is essential for the antileukemic effects of dasatinib. | 2009 Dec |
5 |
| 295 |
19706883 | Acute dasatinib exposure commits Bcr-Abl-dependent cells to apoptosis. | 2009 Oct 15 |
3 |
| 296 |
19779040 | Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations. | 2009 Dec 3 |
5 |
| 297 |
19793709 | Treatment of chronic myeloid leukemia following imatinib resistance: a nursing guide to second-line treatment options. | 2009 Oct |
2 |
| 298 |
19794096 | A novel dasatinib-sensitive RCSD1-ABL1 fusion transcript in chemotherapy-refractory adult pre-B lymphoblastic leukemia with t(1;9)(q24;q34). | 2009 Oct |
1 |
| 299 |
19844167 | Systematically linking drug susceptibility to cancer genome aberrations. | 2009 Nov 15 |
1 |
| 300 |
19878872 | AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. | 2009 Nov 6 |
1 |